Galectin-9 has been observed to be down-regulated in various tumor types, such as melanoma[16], cervical squamous cell cancer[23], breast cancer[24]and hepatocellular carcinoma[25], and it potentially serves as a clinically significant biomarker for predicting outcomes in these patients. The gene discussed is LGALS9; the disease is melanoma.